Junlong Sun1, Wenwu Zhou2, Kangcheng Mao3, Yunfeng He3, Junzhong Yao1, Zhongyu Tang3, Mengruo Song3, Qianqian Liu3, Hui Zhu1, Shaoqing Ju1, Jinlong Shi2, Wei Shi4. 1. Department of Clinic Research Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu, Peoples Republic of China. 2. Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair and Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, Peoples Republic of China; Department of Clinic Research Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu, Peoples Republic of China. 3. Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair and Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, Peoples Republic of China. 4. Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair and Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, Peoples Republic of China; Department of Clinic Research Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu, Peoples Republic of China. Electronic address: ntshiwei123@163.com.
Abstract
OBJECTIVES: To analyze the plasma cell-free DNA (Cf-DNA) in glioma patients with high throughout sequencing for a novel non-invasive method for the early diagnosis and management of glioma. METHODS: Six patients with glioma were recruited from the Affiliated Hospital of Nantong University from June 2015 to September 2016. Their plasma samples were tested for Cf-DNA by whole exon sequencing and mutations were analyzed by bioinformatics. RESULTS: After filtering the raw sequencing data of Cf-DNA, 33,173 mutations were obtained from 12,462 genes of which 442 genes and 655 mutation sites were identical to that in the Catalogue of Somatic Mutations in Cancer database. However, when we compared the Cf-DNA data with the glioma mutated loci in the Cancer Genome Alta database, only 4 mutations matched with the glioma sequences in the Cancer Genome Alta and did not correspond to that of the paired-tumor tissues. CONCLUSIONS: There were some cancer-related somatic mutations in the Cf-DNA of glioma patients, but no identical mutations were found in the paired solid tumors. Therefore, plasma Cf-DNA mutations may not be a suitable marker for the detection of glioma.
OBJECTIVES: To analyze the plasma cell-free DNA (Cf-DNA) in gliomapatients with high throughout sequencing for a novel non-invasive method for the early diagnosis and management of glioma. METHODS: Six patients with glioma were recruited from the Affiliated Hospital of Nantong University from June 2015 to September 2016. Their plasma samples were tested for Cf-DNA by whole exon sequencing and mutations were analyzed by bioinformatics. RESULTS: After filtering the raw sequencing data of Cf-DNA, 33,173 mutations were obtained from 12,462 genes of which 442 genes and 655 mutation sites were identical to that in the Catalogue of Somatic Mutations in Cancer database. However, when we compared the Cf-DNA data with the glioma mutated loci in the Cancer Genome Alta database, only 4 mutations matched with the glioma sequences in the Cancer Genome Alta and did not correspond to that of the paired-tumor tissues. CONCLUSIONS: There were some cancer-related somatic mutations in the Cf-DNA of gliomapatients, but no identical mutations were found in the paired solid tumors. Therefore, plasma Cf-DNA mutations may not be a suitable marker for the detection of glioma.
Authors: Thais S Sabedot; Tathiane M Malta; James Snyder; Kevin Nelson; Michael Wells; Ana C deCarvalho; Abir Mukherjee; Dhananjay A Chitale; Maritza S Mosella; Artem Sokolov; Karam P Asmaro; Adam Robin; Mark L Rosenblum; Tom Mikkelsen; Jack Rock; Laila M Poisson; Ian Lee; Tobias Walbert; Steven Kalkanis; Antonio Iavarone; Ana Valeria Castro; Houtan Noushmehr Journal: Neuro Oncol Date: 2021-09-01 Impact factor: 12.300